NOV 13·Zacks CommentaryMed
Aytu BioPharma Inc. ( AYTU ) Reports Q1 Loss, Tops Revenue Estimates
Aytu BioPharma (AYTU) delivered earnings and revenue surprises of -33.33% and +10.05%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?